Voceryq

News

Inovio Pharma's plasmid DNA-based Voceryq has become the second drug approved in the US for adults with recurrent respiratory papillomatosis.

News

Fresenius is already a player in the biosimilars market, and has ramped up its position via a deal with WuXi Bio that spans up to 37 candidates.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.